Barings’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Barings’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-6,100	Closed	-$220K	–	650
2019 Q4	$220K	Buy	+6,100	New	+$187K	0.01%	577
2019 Q3	–	Sell	-26,500	Closed	-$638K	–	718
2019 Q2	$638K	Buy	26,500 +9,800	+59%	+$249K	0.01%	459
2019 Q1	$441K	Hold	16,700	–	–	0.01%	567
2018 Q4	$326K	Sell	16,700 -150,800	-90%	-$2.96M	0.01%	585
2018 Q3	$3.28M	Buy	+167,500	New	+$3.18M	0.05%	246

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Barings's HZNP Position: Q1 2020 in Review

Barings sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q1 2020, closing a stake of 6,100 shares — an estimated $220K sold.

Barings first reported a position in HZNP in Q3 2018 and held it in 5 quarters. The position peaked at $3.28M in Q3 2018. 295 funds tracked by Wall St. Rank hold HZNP as of Q1 2020.

Barings reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q1 2020 after selling out during the quarter.
Barings sold 6,100 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q1 2020, an estimated $220K.
Barings first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q3 2018 and held it in 5 quarters.
Barings's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $3.28M in Q3 2018.
295 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q1 2020.

Based on Barings's 13F filing for Q1 2020, filed 15 May 2020.